Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer – The ORIENT-16 Randomized Clinical Trial
December 1, 2023
A different PD-1 inhibitor improves survival in patients with unresectable gastric of GEJ tumors, CPS >5, they also had maintenance capecitabine. Confirming role for maintenance immunotherapy.
